Peter Ciszewski
Articles
Trial for Anti-Lung Cancer Compound ASA404 Progresses to Phase III
May 21st 2010A pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis' novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC). NSCLC is the most prevalent cause of cancer death among men and women in the United States and globally.
Read More
Latest Updated Articles
Published: October 4th 2024 | Updated: October 14th 2024
Minimally Invasive Techniques to Manage Complex Polyps at Allegheny Health Network
Published: May 2nd 2024 | Updated: May 6th 2024
Cardiology Month in Review: April 2024
Published: November 16th 2024 | Updated: December 26th 2024
Hide Okuno, MS: Tube Weaning Reduces Parental Stress, Findings Guide Future Studies
Published: November 15th 2024 | Updated: December 26th 2024
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Published: December 16th 2024 | Updated: December 26th 2024
Brilaroxazine Shows Long-Term Efficacy in Schizophrenia in Phase 3 RECOVER
Published: December 16th 2024 | Updated: December 26th 2024
FDA Approves Tapinarof 1% Cream for Adult, Pediatric Patients with Atopic Dermatitis
